Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of viral, bacterial, fungal, and parasitic infections both pretransplant and post-transplant. One of the most dangerous infections that can be acquired during this time is aspergillosis. Several drugs are available for prophylaxis, though no particular regimen has been proven to be superior; although the CDC has clear recommendations regarding prophylaxis for many other infections (such as cytomegalovirus, herpes simplex, toxoplasmosis, and Candida) for HSCT patients, there are none for aspergillosis. Researchers have varying opinions as to which drugs are best for prophylaxis. In this article, pharmacologic and environmental options for prophylaxis are discussed as well as antifungals currently in use, and recommendations on how nurses can help keep their patients safe from this infection are given.
Benet, T., Nicolle, M.C., Thiebaut, A., Piens, M.A., Nicolini, F.E., Thomas, X., et al. (2007). Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clinical Infectious Diseases, 45, 682-686.
2.
Centers for Disease Control. (2000). Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of the CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Retrieved November 16, 2007 , from http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf
3.
Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., et al. (with Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group). (2002). Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine, 347, 408-415.
4.
Hovi, L., Saxen, H., Saarinen-Pihkala, U.M., Vettenranta, K., Meri, T., & Richardson, M. (2007). Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatric Blood Cancer, 48, 28-34.
5.
Madigan, M., & Martinko, J. (2006). Biology of microorganisms. Upper Saddle River, NJ: Pearson/ Prentice Hall.
6.
Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., & Boogaerts, M. (2002). Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. Journal of Infectious Diseases, 186, 1297-1306.
7.
Marr, K.A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. (2004 ). Blood, 103, 1527-1533.
8.
Maschmeyer, G., Haas, A., & Cornely, O.A. (2007). Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients. (2007). Drugs, 67, 1568-1591.
9.
Negrin, R.S. (2007). Preparative regimens for hematopoietic cell transplantation . UpToDate. Retrieved October 10, 2007, from http://healthlinks.washington.edu
10.
Schuster, F., Moelter, C., Schmid, I., Ulrike, I., Graubner, B., Kammer, B., et al. (2005). Successful antifungal combination therapy with voriconazole and caspofungin. Pediatric Blood Cancer , 44, 682-685.
11.
Sulahian, A., Boutboul, F., Ribaud, P., Leblanc, T., Lacroix, C., & Derouin, F. (2001). Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer, 91, 311-318.
12.
Tollemar, J. (1999). Prophylaxis against fungal infections in transplant recipients: Possible approaches. BioDrugs, 11, 309-318.
13.
Ullmann, A.J., & Cornely, O.A. (2006). Antifungal prophylaxis for invasive mycoses in high risk patients. Current Opinion in Infectious Diseases , 19, 571-576.
14.
Ullmann, A.J., Lipton, J.H., Vesole, D.H., Chandrasekar, P., Langston, A., Tarantolo, S.R., et al. (2007). Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New England Journal of Medicine, 356, 335-347.
15.
van Burik, J.H., Ratanatharathorn, V., Stepan, D.E., Miller, C.B., Lipton, J.H., Vesole, D.H., et al. (2004). Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases, 39, 1407-1416.
16.
Winston, D.J., Maziarz, R.T., Chandrasekar, P.H., Lazarus, H.M., Goldman, M., Blumer, J.L., et al. (2003). Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: A multicenter, randomized trial . Annals of Internal Medicine, 138, 705-713.
